Cargando…

Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis

BACKGROUND: Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is one of the leading causes of death in SSc. Identification of a serum-based proteomic diagnostic biomarker for SSc-PAH would allow for rapid non-invasive screening and could positively impact patient survival. Iden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rice, Lisa M., Mantero, Julio C., Stratton, Eric A., Warburton, Rod, Roberts, Kari, Hill, Nicholas, Simms, Robert W., Domsic, Robyn, Farber, Harrison W., Layfatis, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097341/ https://www.ncbi.nlm.nih.gov/pubmed/30115106 http://dx.doi.org/10.1186/s13075-018-1679-8

Ejemplares similares

Correction: Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis
por: Rice, Lisa M., et al.
Publicado: (2022)

Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment
por: Saygin, Didem, et al.
Publicado: (2019)

The HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients
por: Lenna, Stefania, et al.
Publicado: (2015)

Limited Systemic Sclerosis Patients with Pulmonary Arterial Hypertension Show Biomarkers of Inflammation and Vascular Injury
por: Pendergrass, Sarah A., et al.
Publicado: (2010)

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
por: Spiera, Robert, et al.
Publicado: (2020)

Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)
por: Preston, Ioana R., et al.
Publicado: (2015)

Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial
por: Khanna, Dinesh, et al.
Publicado: (2022)

Clinical Application of 2017 McDonald Diagnostic Criteria for Multiple Sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2018)

Myofibroblast transcriptome indicates SFRP2(hi) fibroblast progenitors in systemic sclerosis skin
por: Tabib, Tracy, et al.
Publicado: (2021)

Under pressure: pulmonary hypertension associated with left heart disease
por: Farber, Harrison W., et al.
Publicado: (2015)

A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers
por: Nagaraja, Vivek, et al.
Publicado: (2019)

Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry
por: Chung, Lorinda, et al.
Publicado: (2014)

Management of hospitalized patients with pulmonary arterial hypertension and COVID-19 infection
por: Sahay, Sandeep, et al.
Publicado: (2020)

Reply to Andréasson et al.: Multiple Manifestations of Systemic Sclerosis Affect Walk Distance
por: Zamanian, Roham T., et al.
Publicado: (2021)

The Elephant Man Meets Pulmonary Hypertension. A Cautionary Tale
por: Ruopp, Nicole F., et al.
Publicado: (2020)

Hit Early and Hit Hard in Pulmonary Arterial Hypertension? Not So Fast!
por: Hassoun, Paul M., et al.
Publicado: (2021)

Response to “Noninvasive determinants of pulmonary hypertension (PH) in interstitial lung disease (ILD)” by Joseph et al.
por: Parikh, Raj, et al.
Publicado: (2023)

When “AMBITION” Isn’t Good Enough: Risk Status and Dual Oral Therapy in Pulmonary Arterial Hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2021)

Scleroderma Renal Crisis: A Pathology Perspective
por: Batal, Ibrahim, et al.
Publicado: (2010)

Hypertension Associated with Experimental Serum Nephritis
por: Arnott, W. Melville, et al.
Publicado: (1937)

Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria
por: Fadda, Giulia, et al.
Publicado: (2022)

Unraveling endothelin-1 induced hypercontractility of human pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension
por: Wilson, Jamie L., et al.
Publicado: (2018)

Epoprostenol‐associated ascites in pulmonary arterial hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2022)

Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis
por: Domsic, Robyn T., et al.
Publicado: (2023)

Antibody response to graded dosing of coronavirus disease 2019 messenger RNA vaccines after allergic reaction to first dose
por: Van Meerbeke, Sara W., et al.
Publicado: (2022)

Pulmonary hypertension secondary to takayasu’s arteritis: management using a combined medical and interventional approach
por: Nitzberg, Matthew, et al.
Publicado: (2020)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

CDC2 Is an Important Driver of Vascular Smooth Muscle Cell Proliferation via FOXM1 and PLK1 in Pulmonary Arterial Hypertension
por: Pal-Ghosh, Ruma, et al.
Publicado: (2021)

Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection
por: Parikh, Raj, et al.
Publicado: (2022)

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series
por: Raina, Amresh, et al.
Publicado: (2017)

Tracing and accounting of physical resources in the computer center
por: DOMSIC, Josip
Publicado: (2015)

Pulmonary Tumor Thrombotic Microangiopathy as a Cause of Pulmonary Hypertension
por: Schwartz, Benjamin P., et al.
Publicado: (2021)

Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis
por: Papaioannou, Andriana I, et al.
Publicado: (2009)

The differential diagnostic value of serum homocysteine for white coat hypertension
por: Guo, Shitian, et al.
Publicado: (2017)

Refractory Hepatic Hydrothorax: A Rare Complication of Systemic Sclerosis and Presinusoidal Portal Hypertension
por: Abrams, Gary A., et al.
Publicado: (2018)

Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy
por: Abston, Eric, et al.
Publicado: (2020)

Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review
por: Wesley Milks, Michael, et al.
Publicado: (2021)

An Event-driven Trial for Oral Treprostinil. Progress but Not the Holy Grail
por: Hill, Nicholas S., et al.
Publicado: (2020)

Clinical trial design in phase 2 and 3 trials for pulmonary hypertension
por: Nikkho, Sylvia, et al.
Publicado: (2020)

Use of ultrasound-measured internal jugular vein collapsibility index to determine static intracardiac pressures in patients with presumed pulmonary hypertension
por: Parikh, Raj, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_if4k732pth4pmbjrmpn01toamj